Maxim Group analyst Jason McCarthy maintained a Buy rating on Beyondspring Inc (NASDAQ: BYSI) today and set a price target of $52. The company’s shares closed on Friday at $27.45.
McCarthy observed:
“At ASCO (American BeyondSpring is presenting Phase 2 data for Plinabulin (Plin) vs. Neulasta in the setting of docetaxel chemotherapy for neutropenia. Most important though, in our view, is that Plin is a pivotal small molecule differentiated from Neulasta that is approaching a potential NDA filing in the US (2019)…there are multiple differences from Neulasta that should be focused on, particularly as the Neulasta space moves to biosimilars (i.e. Coherus Biosciences’ {CHRS – Buy} CHS-1701 BSUFA 4Q18).”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 12.6% and a 45.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Beyondspring Inc has an analyst consensus of Moderate Buy, with a price target consensus of $56.
See today’s analyst top recommended stocks >>
The company has a one-year high of $48.49 and a one-year low of $19.55. Currently, Beyondspring Inc has an average volume of 15.42K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.
